Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Li WangNa ZhaoLi ZhouJuan TongLei XueLei ZhangYongsheng HanXingbing WangLiangquan GengBaolin TangHuilan LiuWeibo ZhuXiaoyan CaiXin LiuXiaoyu ZhuZimin SunChang-Cheng ZhengPublished in: Clinical interventions in aging (2022)
Our results showed that standard-intensity induction chemotherapy can significantly improve the CR rate for elderly AML patients, and does not increase the early mortality; consolidation therapy with intermediate or high-dose cytarabine can significantly improve EFS and OS for elderly AML patients achieved CR.
Keyphrases
- acute myeloid leukemia
- high dose
- newly diagnosed
- end stage renal disease
- ejection fraction
- chronic kidney disease
- stem cell transplantation
- middle aged
- allogeneic hematopoietic stem cell transplantation
- peritoneal dialysis
- prognostic factors
- type diabetes
- high intensity
- cardiovascular disease
- community dwelling
- risk factors
- coronary artery disease
- patient reported outcomes
- cardiovascular events
- acute lymphoblastic leukemia
- bone marrow